Dr. Page is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4805 NE Glisan St
Portland, OR 97213Phone+1 503-215-1350Fax+1 503-215-5695
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2015
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Northwestern University The Feinberg School of MedicineClass of 2009
Certifications & Licensure
OR State Medical License 2015 - 2025
NY State Medical License 2011 - 2016- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03
- Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer Start of enrollment: 2021 Sep 10
Publications & Presentations
PubMed
- 20 citationsCTLA-4 Antibodies: New Directions, New CombinationsSamuel Funt, David B. Page, Jedd D. Wolchok, Michael A. Postow
Oncology. 2014-11-11 - 67 citationsCTLA-4 blockade increases antigen-specific CD8 + T cells in prevaccinated patients with melanoma: three casesJianda Yuan, Brian A. Ginsberg, David B. Page, Yanyun Li, Teresa S. Rasalan
Cancer Immunology, Immunotherapy. 2011-04-05 - 351 citationsSingle-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survivalGeoffrey Y. Ku, Jianda Yuan, David B. Page, Sebastian Edoardo Artur Schroeder, Katherine S. Panageas
Cancer. 2010-04-01
Lectures
- A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metast...2019 ASCO Annual Meeting - 6/1/2019
- Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast CancerFebruary 25th, 2021- NanoString Highlights Research Presented at the 2018 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)November 7th, 2018
IRX Therapeutics Announces Presentation of IRX-2 Phase 1b Biomarker Data in Early Stage Breast CancerNovember 10th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
